Optics.org
ECOPTIK
ECOPTIK
daily coverage of the optics & photonics industry and the markets that it serves
Featured Showcases
Photonics West Showcase
Optics+Photonics Showcase
News
Menu
Research & Development

UK cancer imaging centers win £35m funding boost

30 Oct 2013

Nationwide initiative to develop cutting-edge imaging technologies for research.

Cancer Research UK and the Engineering and Physical Sciences Research Council (EPSRC) are together committing £35 million for five years to four separate cancer imaging centers across the country. The new initiative builds on the £50 million initial investment announced in October 2008.

This latest funding will bring together scientists, engineers and clinicians to develop new imaging techniques and applications which will help clinicians learn more about how tumors develop, how cancer cells signal to one another, tumor blood supply, the environment surrounding tumors and molecular and genetic signatures. The cancer imaging centers will serve as focal points of world-class research using a variety of techniques, such as optical microscopy, MRI (magnetic resonance imaging), functional MRI, ultrasound, and PET (Positron Emission Tomography).

Dr Iain Foulkes, Cancer Research UK’s executive director of strategy and research funding, said: “Imaging is an invaluable tool in the fight against cancer. Being able to see what’s happening inside a patient is vitally important in understanding how treatments are working and the best ways to improve them.”

Professor David Delpy, Chief Executive of the EPSRC, said: “This large investment is great news and builds upon our previous successful collaboration with Cancer Research UK. These centers will bring together many of the UK’s leading scientists, engineers and clinicians interested in all aspects of imaging research, speeding up advances in new technologies and ensuring these are applied rapidly for the benefit of patients.”

The four imaging centers to receive funding are at: The University of Oxford, The Institute of Cancer Research, London, a joint imaging centre between King’s College London and University College London and a new collaboration between the University of Cambridge and University of Manchester.

Imaging plays a crucial role in cancer management in three main ways; as an initial assessment of the extent of the cancer at the time of diagnosis, as a tool for guiding therapy and to assess patient response to therapy. The cancer-imaging center in Cambridge and Manchester combines cutting-edge translational research and clinical trials with state-of-the-art imaging, genomics and pre-clinical research. By combining these two locations the cancer-imaging centre has access to a large patient population and vital clinical trials infrastructure.

The cancer-imaging center in Oxford aims to integrate basic research in chemistry, physics and cancer biology with imaging science to guide treatment choices for cancer patients.

The cancer-imaging centre at King’s College London and University College London combine cutting-edge technology development at King’s College London with the genomics expertise and clinical trials as well as access to the first clinical simultaneous PET/MRI facility in the UK. The facility focuses on determining the differences in a patient’s tumor and in bringing new imaging methods to the clinic.

The cancer imaging centre at The Institute of Cancer Research, London is part of the largest comprehensive Cancer Centre in Europe and will focus on enabling ‘personalized’ medicine for each individual patient. New imaging techniques, such as identifying an imaging ‘fingerprint’ of aggressive disease, will help determine which tumors have the greatest risk of progression.

Dr Iain Foulkes added: “This investment will help drive major improvements for cancer patients in the future. Research is unlocking cancer’s secrets and our ability to see what is going on with cancers is essential to better diagnose, monitor and treat cancer patients.”

About the Author

Matthew Peach is a contributing editor to optics.org

CeNing Optics Co LtdOptikos Corporation ABTechTRIOPTICS GmbHBerkeley Nucleonics CorporationAlluxaECOPTIK
© 2024 SPIE Europe
Top of Page